Table 2.
Intralesional methotrexate for treatment of invasive squamous cell carcinoma (modified from Searle et al.) [8].
| Author, Year | n | Location | MTX Administration | Outcome | Adverse Events Related to ilMTX |
|---|---|---|---|---|---|
| Plascencia-Gómez et al., 2014 [44] | 1 | Lower lip | 3 injections of MTX, 1 week apart before surgery; cumulative dose: 75 mg of MTX | 80% tumor size reduction | None reported |
| Moye et al., 2014 [45] | 1 | Multiple SCCs (face, thigh, back, and calf) Patient with melanoma receiving vemurafenib |
4 injections of MTX, 3–4 weeks apart; approximately 1.9–12.5 mg of MTX per injection | All tumors decreased in size | Tolerable pain with injection |
| Salido-Vallejo et al., 2016 [39] | 43 | Cheek (12) > scalp (8) > temple (6) > lower lip (5), arm (5) > nose (3), ear (3) > leg (1) | 1 injection of 25 mg/mL MTX before surgery; mean: 0.74 mL (0.1–1.3 mL) | Reduction in tumor size (mean: 42.6%) compared to surgery alone; greater reduction in lower lip tumors | Discomfort during MTX infiltration (60.47%) |
| Bergón-Sendín et al., 2018 [40] | 10 | Lower lip | 2 injections of 20 mg MTX, 1 week apart before scheduled surgery; cumulative dose: of MTX 40 mg | 100% response Mean decrease in diameter: 68.2% |
None reported |
| Bergón-Sendín et al., 2019 [43] | 40 | Face (50%) > extremities (22.5%) > scalp (17.5%) > trunk (2.5%) | 2 injections of 50 mg/mL MTX, 1 week apart before surgery; mean cumulative dose: 37.6 mg | Clinical and sonographic response in 92.5% | None reported |
| Bergón-Sendín et al., 2020 [41] | 84 | Not reported | 2 injections of MTX before scheduled surgery, 1 week apart; mean cumulative dose: 36.9 mg of MTX | 100% tumor size reduction; 46/84 complete clinical and histopathological response | None reported |
| Gualdi et al., 2020 [38] | 21 | Not reported | 4–6 injections (different protocols, not separated by type of tumor); mean cumulative dose: 133.29 mg of MTX | 47.6% resolution | Yes; anemia the most frequent (5/35) |
| Bergón-Sendín et al., 2021 [42] | 100 | Face (50) > scalp (18) > limbs (16) > lip/ear (14) > trunk (2) | 2 injections of MTX, 1 week apart before scheduled surgery; mean cumulative dose: 37.72 mg of MTX | 93% tumor size reduction; less complex reconstructions than surgery-only group | None reported |
| Vega-González et al., 2022 [46] | 1 | Lower lip | 3 injections of MTX monthly; cumulative dose: 75 mg of MTX | 100% resolution | None reported |
SCC stands for squamous cell carcinoma, KA stands for keratoacanthoma and MTX stands for methotrexate.